Abstract
Blood-borne drug molecules are transported through as well as around cells in tissue. For small molecule drugs with a molar weight < 1000, the wall of the capillary blood vessels in tumors usually is not a barrier. Just after a rise in the drug concentration in the blood, the cells closest to the microvessels are exposed to the highest drug concentrations. Short or long lasting concentration gradients away from the capillary vessels will develop. Since in a tumor the distance to the nearest blood vessel can be relatively large, inefficient transport of drugs to some cancer cells may limit drug efficacy. Studies on in vitro drug gradients have given insight into the factors determining this transport. Small intercellular distances, high cellular drug influx and low drug efflux rates, and high intracellular and extracellular drug binding favor the development of drug gradients. In the absence of drug metabolism, gradients “level out” over time and may reverse as the blood concentration drops. Understanding the drug transport process from the microvessels to every cancer cell will be important for optimizing cancer chemotherapy. Cancer cells that can “hide” for the drug may lead to regrowth of the tumor.
Keywords: drug transport, microcirculation, drug delivery, spheroids, multicellular layers, drug gradients
Current Pharmaceutical Design
Title: Tissue Transport of Anti-cancer Drugs
Volume: 8 Issue: 22
Author(s): Jan Lankelma
Affiliation:
Keywords: drug transport, microcirculation, drug delivery, spheroids, multicellular layers, drug gradients
Abstract: Blood-borne drug molecules are transported through as well as around cells in tissue. For small molecule drugs with a molar weight < 1000, the wall of the capillary blood vessels in tumors usually is not a barrier. Just after a rise in the drug concentration in the blood, the cells closest to the microvessels are exposed to the highest drug concentrations. Short or long lasting concentration gradients away from the capillary vessels will develop. Since in a tumor the distance to the nearest blood vessel can be relatively large, inefficient transport of drugs to some cancer cells may limit drug efficacy. Studies on in vitro drug gradients have given insight into the factors determining this transport. Small intercellular distances, high cellular drug influx and low drug efflux rates, and high intracellular and extracellular drug binding favor the development of drug gradients. In the absence of drug metabolism, gradients “level out” over time and may reverse as the blood concentration drops. Understanding the drug transport process from the microvessels to every cancer cell will be important for optimizing cancer chemotherapy. Cancer cells that can “hide” for the drug may lead to regrowth of the tumor.
Export Options
About this article
Cite this article as:
Lankelma Jan, Tissue Transport of Anti-cancer Drugs, Current Pharmaceutical Design 2002; 8 (22) . https://dx.doi.org/10.2174/1381612023393512
DOI https://dx.doi.org/10.2174/1381612023393512 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Ca2+-Activated K+ Channel of Intermediate Conductance:A Molecular Target for Novel Treatments?
Current Drug Targets Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine Modulation of Hepatic MRP3/ABCC3 by Xenobiotics and Pathophysiological Conditions: Role in Drug Pharmacokinetics
Current Medicinal Chemistry Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients
Current Pharmaceutical Design Different 6-Aryl-Fulvenes Exert Anti-proliferative effects on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Titanocenes as Anticancer Agents: Recent Insights
Medicinal Chemistry Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds
Current Pharmaceutical Design Roles of SM22α in Cellular Plasticity and Vascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) Controlled-release Particulate Cytokine Adjuvants for Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer?
Current Cancer Drug Targets Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
Current Pharmaceutical Design B Cell Modulation Strategies in Autoimmunity: The SLE Example
Current Pharmaceutical Design New Anti-Angiogenic Targeted Therapy in Advanced Renal Cell Carcinoma (RCC):Current Status and Future Prospects
Reviews on Recent Clinical Trials Management of Gene Variants of Unknown Significance: Analysis Method and Risk Assessment of the VHL Mutation p.P81S (c.241C>T)
Current Genomics In Vivo Inhibition of the Estrogen Sulfatase Enzyme and Growth of DMBA-Induced Mammary Tumors by Melatonin
Current Cancer Drug Targets The Prevention of Oral Mucositis in Patients with Blood Cancers: Current Concepts and Emerging Landscapes
Cardiovascular & Hematological Agents in Medicinal Chemistry miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke
MicroRNA Nitric Oxide Synthase and Cyclooxygenase Pathways: A Complex Interplay in Cellular Signaling
Current Medicinal Chemistry